Deep vein thrombosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
| Line 6: | Line 6: | ||
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer<ref>http://clinicaltrials.gov/ct2/show/NCT00633893<ref | Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer<ref>http://clinicaltrials.gov/ct2/show/NCT00633893</ref> | ||
* Primary Outcome Measures: Venous Thromboembolic Recurrence or Death | * Primary Outcome Measures: Venous Thromboembolic Recurrence or Death | ||
* Secondary Outcome Measures: Bleeding | * Secondary Outcome Measures: Bleeding | ||
Revision as of 01:32, 20 June 2012
Ongoing Research
Phase 3 Trials
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer[1]
- Primary Outcome Measures: Venous Thromboembolic Recurrence or Death
- Secondary Outcome Measures: Bleeding
- Estimated Enrollment: 2,430 patients
- Study Start Date: May 2008
- Estimated Study Completion Date: August 2012